Month: March 2025
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — On March 26, 2025, Satellogic Inc. (NASDAQ: SATL) (the “Company”), consummated its previously announced domestication, pursuant to which the Company changed its jurisdiction of incorporation, domesticating as a corporation incorporated under the laws of the State of Delaware and discontinuing as a business company with limited liability incorporated under the laws of the British Virgin Islands. The Company’s business, assets and liabilities on a consolidated basis, as well as its Board of Directors, the Company’s executive officers, principal business locations (other than its principal executive office) and fiscal year, were the same immediately after the domestication as they were immediately prior to the domestication. Additionally, the Company’s Class A common stock will continue...
Invesco Ltd: Form 8.3 – NIOX Group PLC; Public dealing disclosure
Written by Customer Service on . Posted in Mergers And Acquisitions.
FORM 8.3
PUBLIC DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1.
KEY INFORMATION
(a)
Full name of discloser:
Invesco Ltd.
(b)
Owner or controller of interests and short positions disclosed, if different from 1(a):The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)
Name of offeror/offeree in relation to whose relevant securities this form relates:Use a separate form for each offeror/offeree
NIOX Group plc
(d)
If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)
Date position held/dealing undertaken:For an opening position disclosure, state the latest practicable date prior to...
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
Written by Customer Service on . Posted in Public Companies.
PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. The details are listed below. The abstracts will be published in the online Proceedings of the AACR.
Poster 1: Title: Bria-ABC1 vs physician choice in late-stage MBC; early biomarker correlates of the randomized registration trialSession Title: Late-Breaking Research: Clinical Research 4Session Date and Time: 4/30/2025 9:00 AM –...
OSS Announces Order from Innovative Medical Imaging OEM
Written by Customer Service on . Posted in Public Companies.
Current contract valued at approximately $500,000 with expected follow-on production orders valued at over $25 million over the next five years
ESCONDIDO, Calif., March 26, 2025 (GLOBE NEWSWIRE) — One Stop Systems, Inc. (OSS or the Company) (Nasdaq: OSS), a leader in rugged Enterprise Class compute for artificial intelligence (AI), machine learning (ML) and sensor processing at the edge, today announced a new $500,000 contract from a medical imaging OEM customer that is expected to contribute to revenue throughout 2025.
Under the terms of the contract, OSS will provide 4U, short-depth-server (SDS) running Enterprise Class NVIDIA GPUs to support a customer’s innovative, FDA cleared, medical imaging technology for Breast Scanning. After this initial order, OSS expects follow-on orders from this medical OEM for next-generation liquid-cooled...
National Healthcare Properties Announces Preferred Stock Dividends
Written by Customer Service on . Posted in Dividend Reports And Estimates.
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) — National Healthcare Properties, Inc. (Nasdaq: NHPAP / NHPBP) (“NHP”) announced today that it declared quarterly dividends on its outstanding preferred stock. Specifically, NHP declared a dividend of $0.4609375 per share on its 7.375% Series A Cumulative Redeemable Perpetual Preferred Stock payable on April 15, 2025 to holders of record at the close of business on April 4, 2025. In addition, NHP declared a dividend of $0.4453125 per share on its 7.125% Series B Cumulative Redeemable Perpetual Preferred Stock payable on April 15, 2025 to holders of record at the close of business on April 4, 2025.
About National Healthcare Properties, Inc.
National Healthcare Properties, Inc. (Nasdaq: NHPAP / NHPBP) is a publicly registered real estate investment trust focused on acquiring a diversified...
Zelluna ASA [ZLNA]: Share capital increase resolution
Written by Customer Service on . Posted in Public Companies.
Oslo, Norway, 26 March, 2025
Reference is made to the stock exchange notice published on 9 January 2025 regarding an extraordinary general meeting held in Zelluna ASA (the “Company“), where it was resolved to carry out a reverse share split in the ratio 10:1 and to grant the Company’s board of directors a general authorisation to issue shares. As the Company’s shares cannot be fully divided by 10, the Company’s board of directors has today resolved a share capital increase of NOK 0.70 through the issuance of seven (7) new shares, each with a par value of NOK 0.10, and a subscription price of NOK 2.60 per share.
The shares were subscribed for by Radforsk Investeringsstiftelse. A separate notification regarding transaction by persons discharging managerial responsibilities (PDMRs) will be published shortly....
TRANSFER OF HARVIA’S OWN SHARES AS REWARDS UNDER THE INCENTIVE PROGRAM
Written by Customer Service on . Posted in Public Companies.
HARVIA PLC STOCK EXCHANGE RELEASE March 26, 2025 AT 2.15 P.M. EET
The Board of Directors of Harvia Plc has on 25 February 2025 decided on a directed share issue without consideration for the payment of rewards earned under the company’s share-based incentive program. The share payments concern the performance period 2022–2024 of the company’s share-based incentive program launched in 2022.
In the share issue, 9,852 own shares held by the company have today been transferred without consideration to the key employees participating in the share-based incentive program in accordance with the terms and conditions of the program.
The company holds a total of 5,355 own shares after the transfer of shares under the incentive program.
The decision on the transfer of shares is...
SAIC Announces ReadyOne™ Foundational: Latest Digital Engineering Ecosystem for Accelerated Innovation and Mission Effectiveness
Written by Customer Service on . Posted in Public Companies.
RESTON, Va., March 26, 2025 (GLOBE NEWSWIRE) — Science Applications International Corp. (NASDAQ: SAIC) has announced the launch of ReadyOne™ Foundational – the company’s commercial-grade solution for a rapidly deployable, cloud-based digital engineering ecosystem that meets the Department of Defense (DoD) Instruction 5000.97 mandate and unique mission requirements of government customers. It is now available on the AWS Marketplace to accelerate deployment and help government avoid developing capabilities that are already commercially available.
ReadyOne™ Foundational’s built-in digital thread accelerator unifies disparate data, tools and teams in real-time through a configurable, turnkey solution – enabling an out-of-the-box adoption of best practices in digital engineering. This offering grants customers access...
VERSES® Announces Consolidation of Class A Subordinate Voting Shares in Preparation for a Planned Uplisting to NASDAQ
Written by Customer Service on . Posted in Public Companies.
VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE:VERS) (OTCQB:VRSSF) (“VERSES” or the “Company”) a cognitive computing company specializing in next-generation intelligent software systems, is pleased to announce the consolidation of its Class A Subordinated Voting Shares in connection with an application to uplist such shares on the Nasdaq Capital Market (“Nasdaq”).
As part of the planned uplisting, the Company is consolidating all issued and outstanding Class A Subordinate Voting Shares (“Subordinated Voting Shares”) on the basis of one (1) post-consolidated Subordinated Voting Share for every nine (9) pre-consolidated Subordinated Voting Share held (the “Consolidation”).
“The consolidation is one of many initiatives that the Company is implementing in preparation for our intended...
Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025
Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD)
Cash of $69.8 million as of December 31, 2024, expected to fund operations into 2027
LONDON, March 26, 2025 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2024, and provided recent corporate highlights.
“2024 was a year of focused execution and strategic advancement at Mereo, driving our lead programs closer to key milestones,” said Dr. Denise Scots-Knight, Chief Executive Officer...
